PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical and Molecular Hepatology10.3350/cmh.2022.00472022283575-579Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinomaHideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura, http://e-cmh.org/upload/pdf/cmh-2022-0047.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2022.0047, http://e-cmh.org/upload/pdf/cmh-2022-0047.pdf
Cancers10.3390/cancers13215475202113215475Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination TherapyMasatoshi Kudohttps://www.mdpi.com/2072-6694/13/21/5475/pdf
10.21203/rs.3.rs-1722962/v12022Perfusion Change of Hepatocellular Carcinoma during Atezolizumab plus Bevacizumab Treatment: A Pilot StudyEzinwanne Onuoha, Andrew D. Smith, Robert Cannon, Mohd Khushman, Harrison Kimhttps://www.researchsquare.com/article/rs-1722962/v1, https://www.researchsquare.com/article/rs-1722962/v1.html
Journal of Clinical and Experimental Hepatology10.1016/j.jceh.2022.07.00320221261575-1576Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular CarcinomaAkash Royhttps://api.elsevier.com/content/article/PII:S0973688322001682?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0973688322001682?httpAccept=text/plain
The Lancet Oncology10.1016/s1470-2045(20)30476-92020219e413Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma – Authors' replysKyung-Hun Lee, Michael S Leehttps://api.elsevier.com/content/article/PII:S1470204520304769?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1470204520304769?httpAccept=text/plain
Liver Cancer10.1159/000514312202110285-93Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination TherapyMasatoshi Kudohttps://www.karger.com/Article/Pdf/514312, https://www.karger.com/Article/Pdf/514312
Liver Cancer10.1159/000505189202092119-137A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination TherapyMasatoshi Kudohttps://www.karger.com/Article/Pdf/505189, https://www.karger.com/Article/Pdf/505189
The Lancet Oncology10.1016/s1470-2045(20)30430-72020219e412Atezolizumab plus bevacizumab for unresectable hepatocellular carcinomaXu Yang†, Dongxu Wang†, Jianzhen Lin, Xiaobo Yang, Haitao Zhaohttps://api.elsevier.com/content/article/PII:S1470204520304307?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1470204520304307?httpAccept=text/plain
Liver Cancer10.1159/0005204812021112180-181Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaAlessandro Rizzo, Angela Dalia Ricci, Giovanni Brandihttps://www.karger.com/Article/Pdf/520481, https://www.karger.com/Article/Pdf/520481
Clinical Radiology10.1016/s0009-9260(96)80123-11996515379-381Case report: Pseudoglandular hepatocellular carcinoma: Discrepancy between CT and MR findingsK. Ito, T. Yoshimizu, T. Nakanishihttps://api.elsevier.com/content/article/PII:S0009926096801231?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0009926096801231?httpAccept=text/plain